Layered Systems for Oral Peptides

Evidence

Peptides taken by mouth face several obstacles in sequence: stomach conditions can destabilize a formulation, digestive enzymes can cut the peptide, and the intestinal lining can restrict absorption. Two independent studies built layered systems around those problems. They used different peptides and reached different stages of testing, but each combined physical positioning with chemical formulation rather than relying on a single enhancer.

The newer study, first published July 23, tested insulin in a self-unfolding polymer foil. The foil was designed to release its payload in one direction and close to the intestinal mucosa. Its cavities held an ionogel made with choline decanoate, a permeation-enhancing material, while hydrophilic surface modification and cavity design were used to optimize insulin release. In rats, the combined system produced 12.5% bioavailability and 20% biopotency relative to subcutaneous insulin. Those values were approximately threefold and fourfold higher, respectively, than the formulation-control group. The source available for this briefing is the PubMed abstract, so it supports those reported comparisons but not an independent examination of group sizes, variability, or every control.

The second study developed a two-tier system for exenatide, a GLP-1 peptide. The researchers first formed a hydrophobic ion pair between exenatide and sodium docusate at a 1:4 molar ratio. That step made the peptide more compatible with lipids. Their optimized formulation contained 85% Labrafac MC60, 10% Kolliphor RH40, and 5% propylene glycol; its reported particle size was 106 nanometers. It carried 6 milligrams of solubilized exenatide per gram and 20 milligrams of sodium caprate per gram as an additional permeation enhancer.

In an alpha-chymotrypsin assay, unformulated exenatide was completely degraded within minutes, whereas about 80% of exenatide in the hydrophobic-ion-pair lipid formulation remained after 60 minutes. Adding sodium caprate did not significantly change the protection measured at 60 minutes. The formulation also exposed a tradeoff: over four weeks, the solubilized ion-paired peptide formed more impurities than suspended exenatide acetate at room temperature, and sodium caprate accelerated degradation under that condition.

The capsule layer created another engineering test. A standard enteric capsule developed holes in three of six samples during acidic testing. The team replaced its inner structural layer with gelatin and retained an outer HPMC-AS enteric layer. Customized capsules filled with the formulation remained intact for one hour in acid and opened within five minutes after transfer to pH 6.8 buffer. This demonstrates controlled release under laboratory conditions, not oral bioavailability: the exenatide system did not proceed to animal pharmacokinetic or efficacy testing in this study.

Analysis — Functional Layers Solve Different Barriers

The cross-study pattern is functional division of labor. The ionogel provides a chemical route to greater permeation, while the unfolding foil concentrates release toward the intestinal surface. In the exenatide system, the enteric shell handles gastric transit, the lipid droplets limit enzymatic access, hydrophobic ion pairing keeps the peptide associated with that lipid environment, and permeation enhancers are released at the same site. This is an analysis of converging design logic, not evidence that the two platforms are interchangeable or ready for clinical use.

The contrast between the studies is especially informative. The insulin foil produced in vivo exposure data, but its abstract-level record leaves many experimental details unavailable. The exenatide paper documents formulation composition, protease protection, capsule failure, redesign, and stability costs in full text, yet stops before in vivo testing. Together they support an emerging hypothesis: successful oral delivery may require coordinated control over both peptide integrity and the location of release. A direct test would hold the peptide and enhancer constant, then compare diffuse release with mucosa-directed release while measuring intact peptide, local tissue effects, systemic exposure, and variability.

Limitations

Neither study establishes clinical effectiveness or safety. The insulin experiment was conducted in rats, and relative bioavailability does not show that repeated use would be predictable, well tolerated, or manufacturable at scale. Because only its abstract was ingested, this briefing cannot assess sample size, confidence intervals, detailed glucose-response methods, intestinal findings, device transit, or off-target effects. The authors' statement that the result is the platform's highest bioavailability to date is a within-platform comparison, not evidence of superiority to every oral insulin approach.

The exenatide work was primarily in vitro. Alpha-chymotrypsin protection and pH-triggered capsule opening simplify the changing enzyme mixtures, fluid volumes, motility, mucus, food effects, and transit times encountered in an animal or person. Its four-week stability findings also show that better solubilization can accompany faster impurity formation. The studies used different peptides, controls, endpoints, and development stages, so their results cannot be pooled quantitatively. Replication, complete pharmacokinetics, intact-peptide measurements, longer stability testing, local-toxicity assessment, and head-to-head component controls would be needed to determine whether layered delivery produces a reproducible advantage.